altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Company profile
Ticker
ALT
Exchange
Website
CEO
Vipin Garg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEALTHCARE ACQUISITION CORP, PHARMATHENE, INC
SEC CIK
Corporate docs
Subsidiaries
Altimmune, LLC • Altimmune UK, Limited • Spitfire Pharma, LLC • Altimmune AU Pty, Limited ...
IRS number
202726770
ALT stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 24
8-K
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
30 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
7 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
ARS
2022 FY
Annual report to shareholders
16 Aug 23
DEF 14A
Definitive proxy
16 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
ALT
Earnings call transcript
2023 Q4
27 Mar 24
ALT
Earnings call transcript
2023 Q3
7 Nov 23
ALT
Earnings call transcript
2023 Q2
10 Aug 23
ALT
Earnings call transcript
2023 Q1
11 May 23
ALT
Earnings call transcript
2022 Q4
28 Feb 23
ALT
Earnings call transcript
2022 Q3
10 Nov 22
ALT
Earnings call transcript
2022 Q2
11 Aug 22
ALT
Earnings call transcript
2022 Q1
12 May 22
ALT
Earnings call transcript
2021 Q4
15 Mar 22
ALT
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
SC 13G
MILLENNIUM MANAGEMENT LLC
5 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Nuveen Asset Management, LLC
14 Feb 24
SC 13G/A
TEACHERS ADVISORS, LLC
14 Feb 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
14 Feb 24
SC 13G
AMERIPRISE FINANCIAL INC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 86.90 mm | 86.90 mm | 86.90 mm | 86.90 mm | 86.90 mm | 86.90 mm |
Cash burn (monthly) | 5.17 mm | 3.38 mm | 7.51 mm | 7.12 mm | 6.83 mm | 6.38 mm |
Cash used (since last report) | 34.40 mm | 22.53 mm | 50.03 mm | 47.39 mm | 45.47 mm | 42.50 mm |
Cash remaining | 52.50 mm | 64.37 mm | 36.87 mm | 39.51 mm | 41.42 mm | 44.40 mm |
Runway (months of cash) | 10.2 | 19.0 | 4.9 | 5.6 | 6.1 | 7.0 |
Institutional ownership, Q3 2023
25.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 147 |
Opened positions | 33 |
Closed positions | 22 |
Increased positions | 39 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 309.59 bn |
Total shares | 17.78 mm |
Total puts | 978.10 k |
Total calls | 456.30 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
Tiaa Cref Investment Management | 2.21 mm | $20.24 mm |
Teachers Advisors | 2.21 mm | $20.24 mm |
Franklin Mutual Advisers | 1.31 mm | $0.00 |
BEN Franklin Resources | 1.30 mm | $35.20 bn |
BLK Blackrock | 957.28 k | $25.88 bn |
Vanguard | 736.69 k | $19.91 bn |
Neuberger Berman | 691.14 k | $18.66 bn |
Marshall Wace | 565.36 k | $15.28 bn |
D. E. Shaw & Co. | 538.76 k | $14.56 bn |
Arrowstreet Capital, Limited Partnership | 423.23 k | $11.41 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Feb 24 | Matthew Scott Harris | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 9.32 | 2,332 | 21.73 k | 53,633 |
2 Feb 24 | Matthew Scott Harris | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 7,775 | 0.00 | 55,965 |
2 Feb 24 | Matthew Scott Harris | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 7,775 | 0.00 | 15,550 |
2 Feb 24 | Vipin K Garg | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 9.32 | 8,376 | 78.06 k | 292,028 |
2 Feb 24 | Vipin K Garg | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 18,950 | 0.00 | 300,404 |
2 Feb 24 | Vipin K Garg | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 18,950 | 0.00 | 37,900 |
2 Feb 24 | M Scot Roberts | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 9.32 | 2,330 | 21.72 k | 42,660 |
2 Feb 24 | M Scot Roberts | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 7,775 | 0.00 | 44,990 |
2 Feb 24 | M Scot Roberts | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 7,775 | 0.00 | 15,550 |
1 Feb 24 | Matthew Scott Harris | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 9.88 | 1,801 | 17.79 k | 48,190 |
News
How Is The Market Feeling About Altimmune?
8 Apr 24
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
3 Apr 24
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12
1 Apr 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
27 Mar 24
Press releases
Thinking about buying stock in Ocugen, Ceragon Networks, Gannett, Altimmune, or Nio?
1 Apr 24
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 24
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
20 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
7 Mar 24
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
5 Mar 24